StockData
Alto Neuroscience, Inc. logo

Alto Neuroscience, Inc. (ANRO) company profile

ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$24.91−2.21 (-8.15%)

Close on Nov 17, 2026Market cap $977.52MP/E –Yield –

About Alto Neuroscience

Pharmaceutical Preparations, SIC 2834

Alto is a clinical-stage biopharmaceutical company that develops targeted therapies for neuropsychiatric conditions. The company utilizes a proprietary precision psychiatry platform that evaluates brain-based biomarkers through electroencephalography, neurocognitive assessments, wearable technology, and genomic data to identify patients likely to benefit from specific interventions. Its clinical development pipeline comprises seven assets, including ALTO-207, ALTO-300, ALTO-100, ALTO-101, and ALTO-203, targeting disorders such as major depressive disorder, bipolar depression, treatment-resistant depression, cognitive impairment associated with schizophrenia, and Parkinson’s disease. Its products are developed for individuals diagnosed with psychiatric and neurological disorders.

The company conducts clinical trials across the United States, having gathered biomarker data from over 2,000 participants across more than 70 clinical sites. Its clinical operations also examine compounds previously evaluated or approved in international regions including Europe and Australia. The provided text does not disclose the location of its corporate headquarters.

Summary of the business section of Alto Neuroscience's latest annual report, written by StockData.

Company profile

Company

Legal name
Alto Neuroscience, Inc.
Founded
2019
Headquarters
Mountain View, CA
Address
650 Castro Street, Suite 450 94041
Phone
(773) 255-5012
Employees
68, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Chicago, Illinois

Stock & identifiers

Ticker
ANRO
Exchange
NYSE
IPO date
Feb 5, 2024
Shares outstanding
39M, Aug 7, 2026
Public float
$55.20M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1999480
CUSIP
02157Q109
ISIN
US02157Q1094
FIGI
BBG00WYFS6R5
Share class FIGI
BBG00WYFS6S4
EIN
83-4210124

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Amit EtkinPRESIDENT AND CEO, Director833,949
Nicholas Conrad SmithPRESIDENT AND CFO79,060
Adam SavitzCHIEF MEDICAL OFFICER39,851
Jr. Michael Conick HanleyCHIEF OPERATING OFFICER–
Andrew Craig MillerDirector–
Gwill YorkDirector23,917
Christopher Nixon CoxDirector588,898
Andrew DreyfusDirector–
Husseini ManjiDirector–
Ramiro SanchezDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Amit Etkin, M.D., Ph.D.
President, Chief Executive Officer, and Chair of the Board
$650.67K–$934.19K$358.07K$25.56K$2.19M-46%
Nicholas Smith
Chief Financial Officer and Chief Business Officer
$493.72K$220.00K$594.72K$222.30K$10.84K$1.54M-23%
Michael Hanley
Chief Operating Officer
$488.80K–$517.60K$195.52K$11.01K$1.21M-50%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 5, 2024
Offer price
$16.00
Securities offered
8,040,000
Gross proceeds
$128.64M
Exchange
NYSE
First trading day
Feb 2, 2024
First-day close
$20.70+29.4%
Lock-up ends (est.)
Jul 31, 2024

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 68 total employees, including 66 in the United States and two in Australia.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?